Novel psychoactive substances: the pharmacology of stimulants and hallucinogens
| Autor: | Laura Orsolini, John Corkery, G Duccio Papanti, Fabrizio Schifano |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Hallucinogen
medicine.medical_specialty Future studies Fever Screening test Substance-Related Disorders medicine.medical_treatment Pharmacology Rhabdomyolysis Benzodiazepines 03 medical and health sciences 0302 clinical medicine Dopamine medicine Animals Humans Pharmacology (medical) General Pharmacology Toxicology and Pharmaceutics Psychiatry Propofol Psychotropic Drugs Aggression business.industry General Medicine 030227 psychiatry Substance Abuse Detection First line treatment Hallucinogens Central Nervous System Stimulants Cannabinoid medicine.symptom business 030217 neurology & neurosurgery Antipsychotic Agents medicine.drug |
| Zdroj: | Expert Review of Clinical Pharmacology. 9:943-954 |
| ISSN: | 1751-2441 1751-2433 |
| DOI: | 10.1586/17512433.2016.1167597 |
| Popis: | There are increasing levels of concern relating to the rapidly evolving novel psychoactive substances/NPS and web markets' scenarios. The paper aims at providing an overview of the clinical pharmacological issues related to some of the most popular NPS categories, e.g. stimulants and hallucinogens. NPS intake is typically associated with the imbalance of a complex range of neurotransmitter pathways/receptors, namely: dopamine; cannabinoid/CB1; and 5-HT2A. The intake is almost invariably undetectable with standard screening tests. Hence, it may frequently occur that the acute management of NPS misusers will need to focus on decreasing levels of both self/outward-directed aggression and agitation. Benzodiazepines may be considered as first line treatment. Alternatively, propofol and/or antipsychotics can be administered. Focus will be as well on treatment of possible rhabdomyolysis and hyperthermia. Indeed, future studies should inform better tailored management/treatment strategies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|